Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of HLCR011 in retinal pigment epithelium tear
jRCT2073230077Phase 2Recruiting
- Sponsor
- Sumitomo Pharma
- Start
- Apr 2024
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iPS-derived corneal cell therapy in Retinal Pigment Epithelial Tear and exudative macular degeneration, sponsored by Sumitomo Pharma. Primary endpoint: Safety (adverse events). Started Apr 2024; status: recruiting.
02
Drugs
iPS-derived corneal cell therapy
03
Conditions
Retinal Pigment Epithelial Tearexudative macular degeneration
Beyond the preview
Go deeper on jRCT2073230077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2073230077.